[[1]](#footnote-2)



**March 17, 2025**

**Reinsurance Coverage of Three Additional High-Cost Specialty Drugs (BIO)**

AHCCCS is pleased to announce the addition of the following drugs to the High-Cost Specialty Drug Reinsurance Program effective October 1, 2024 and include the following:

**Bylvay** (Odevixibat) is FDA approved to treat Progressive Familial Intrahepatic Cholestasis (PFIC).

**Cholbam** (cholic acid) is FDA approved treat the following:

* Bile acid synthesis disorders due to single enzyme defects; and
* Adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption.

**Effective October 1, 2025:**

**Aucatzyl** (obecabtagene autoleucel) is a T cell immunotherapy FDA approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The Request Letter for Catastrophic Reinsurance, on the AHCCCS website, will be updated with the new high-cost specialty drugs in the next few days. If your plan has a member that received Bylvay or Cholbam on or after the effective date of October 1, 2024, you may submit a reinsurance request to AHCCCS Medical Management. The request must be received by AHCCCS Medical Management prior to May 1, 2025.

1. [↑](#footnote-ref-2)